Kevin K. Wang

USA

Dr. Kevin Wang has been an innovator in CNS therapeutics and theranostic biomarkers, as well as a translational neuroscientist for over 35 years. He previously held leadership positions at Parke-Davis Pharmaceutical and Pfizer Global R&D.  two acute TBI blood-based protein biomarkers (UCH-L1/GFAP) that he co-discovered and developed in vitro diagnostic (IVD) tests for have received FDA and EMA regulatory clearance as the first-in-class IVD blood test to aid in the diagnosis of mild TBI patients with brain lesions. These markers together with NFL , Tau and pTau  are also gaining momentum for their diagnostic potentials in AD and other neurodegeneration.   These TBI blood tests are now on the market under the Abbott i-STAT Anility and bioMérieux VIDAS.  Dr. Wang is also a key opinion leader in brain injuries and neurodegeneration. And serve as a subject matter expert for the NIH, the Department of Defense (DOD), and the Veterans Administration (VA) on these topics.